Short Interest in Klotho Neurosciences, Inc. (NASDAQ:KLTO) Grows By 163.8%

Klotho Neurosciences, Inc. (NASDAQ:KLTO) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling 1,033,627 shares, a growth of 163.8% from the January 15th total of 391,815 shares. Based on an average trading volume of 590,981 shares, the days-to-cover ratio is presently 1.7 days. Approximately 1.6% of the shares of the stock are sold short. Approximately 1.6% of the shares of the stock are sold short. Based on an average trading volume of 590,981 shares, the days-to-cover ratio is presently 1.7 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Klotho Neurosciences in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Klotho Neurosciences

Institutional investors and hedge funds have recently made changes to their positions in the stock. Brummer Multi Strategy AB purchased a new position in Klotho Neurosciences in the fourth quarter worth approximately $175,000. Geode Capital Management LLC increased its position in shares of Klotho Neurosciences by 51.8% in the 4th quarter. Geode Capital Management LLC now owns 491,832 shares of the company’s stock valued at $142,000 after purchasing an additional 167,905 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Klotho Neurosciences in the 2nd quarter valued at $26,000. 20.07% of the stock is owned by hedge funds and other institutional investors.

Klotho Neurosciences Stock Down 6.1%

Shares of KLTO traded down $0.01 during midday trading on Thursday, reaching $0.22. The company had a trading volume of 298,501 shares, compared to its average volume of 586,029. The firm has a 50 day simple moving average of $0.33 and a 200-day simple moving average of $0.51. The stock has a market cap of $15.92 million, a PE ratio of -0.68 and a beta of 10.27. Klotho Neurosciences has a 1-year low of $0.11 and a 1-year high of $3.91.

Klotho Neurosciences (NASDAQ:KLTO) last posted its quarterly earnings results on Thursday, November 13th. The company reported ($0.05) earnings per share for the quarter.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases.